Skip to main content
BSX
NYSE Life Sciences

Boston Scientific Stock Plunges 9% to 2-Year Low on Negative Re-evaluation of Watchman FLX Trial Data

Tom Rudovsky · Reported by Dow Jones Newswires
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$62.81
Mkt Cap
$93.203B
52W Low
$61.245
52W High
$109.5
52W Position info
2.6% above low
Off High info
43% below high
Rel. Volume info
2.1× avg
Market data snapshot near publication time

BSX is trading near its 52-week low of $61.245 (2.6% above the low) on elevated volume (2.1× avg).

Summary

Boston Scientific's stock plummeted 9.1% to a two-year low after investors negatively re-evaluated clinical trial data for its Watchman FLX heart implant. While the company initially announced "highly positive results" from the CHAMPION-AF trial on March 28th, the market is now focusing on a numerically higher rate of ischemic strokes (3.2% vs 2%) in Watchman users compared to blood thinners. This concern overshadowed the device's non-inferiority to blood thinners and reduced bleeding, leading to a significant sell-off. The substantial stock drop indicates that the market perceives a material risk or competitive disadvantage, despite company officials and some analysts remaining optimistic about the overall data. Investors will closely watch for further long-term data, particularly the five-year follow-up on ischemic stroke rates, and any potential impact on Watchman FLX adoption.

At the time of this announcement, BSX was trading at $62.81 on NYSE in the Life Sciences sector, with a market capitalization of approximately $93.2B. The 52-week trading range was $61.25 to $109.50. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.


Price Chart

Share this article

Copied!

BSX - Latest Insights

BSX
Nov 02, 2026, 5:54 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $44.16
Real-time Price: $45.33 info
Change: +$1.17 (+3%) info
Market Cap: $65.697B info
BSX
Nov 02, 2026, 5:26 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $44.24
Real-time Price: $45.33 info
Change: +$1.09 (+2%) info
Market Cap: $65.697B info
BSX
Oct 29, 2026, 3:00 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $42.15
Real-time Price: $45.33 info
Change: +$3.17 (+8%) info
Market Cap: $65.697B info
BSX
Oct 28, 2026, 10:52 AM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $42.11
Real-time Price: $45.33 info
Change: +$3.22 (+8%) info
Market Cap: $65.697B info
BSX
Oct 28, 2026, 6:34 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $42.85
Real-time Price: $45.33 info
Change: +$2.48 (+6%) info
Market Cap: $65.697B info